Literature DB >> 29523642

Psychiatric comorbidity is associated with disability progression in multiple sclerosis.

Kyla A McKay1, Helen Tremlett1, John D Fisk1, Tingting Zhang1, Scott B Patten1, Lorne Kastrukoff1, Trudy Campbell1, Ruth Ann Marrie2.   

Abstract

OBJECTIVE: Emerging evidence suggests that comorbidity may influence disability outcomes in multiple sclerosis (MS); we investigated the association between psychiatric comorbidity and MS disability progression in a large multiclinic population.
METHODS: This retrospective cohort study accessed prospectively collected information from linked clinical and population-based health administrative databases in the Canadian provinces of British Columbia and Nova Scotia. Persons with MS who had depression, anxiety, or bipolar disorder were identified using validated algorithms using physician and hospital visits. Multivariable linear regression models fitted using an identity link with generalized estimating equations were used to determine the association between psychiatric comorbidity and disability using all available Expanded Disability Status Scale (EDSS) scores.
RESULTS: A total of 2,312 incident cases of adult-onset MS were followed for a mean of 10.5 years, during which time 35.8% met criteria for a mood or anxiety disorder. The presence of a mood or anxiety disorder was associated with a higher EDSS score (β coefficient = 0.28, p = 0.0002, adjusted for disease duration and course, age, sex, socioeconomic status, physical comorbidity count, and disease-modifying therapy exposure). Findings were statistically significant among women (β coefficient = 0.31, p = 0.0004), but not men (β coefficient 0.22, p = 0.17).
CONCLUSION: Presence of psychiatric comorbidities, which were common in our incident MS cohort, increased the severity of subsequent neurologic disability. Optimizing management of psychiatric comorbidities should be explored as a means of potentially mitigating disability progression in MS.
© 2018 American Academy of Neurology.

Entities:  

Mesh:

Year:  2018        PMID: 29523642      PMCID: PMC5894930          DOI: 10.1212/WNL.0000000000005302

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  35 in total

1.  Disability in a community population with MS with and without mental disorders.

Authors:  Scott B Patten; Jeanne V A Williams; Dina H Lavorato; Luanne M Metz; Andrew G M Bulloch
Journal:  Int J Psychiatry Med       Date:  2012       Impact factor: 1.210

2.  Prevalence and incidence of ischemic heart disease in multiple sclerosis: A population-based validation study.

Authors:  Ruth Ann Marrie; Bo N Yu; Stella Leung; Lawrence Elliott; Patricia Caetano; Sharon Warren; Christina Wolfson; Scott B Patten; Lawrence W Svenson; Helen Tremlett; John Fisk; James F Blanchard
Journal:  Mult Scler Relat Disord       Date:  2013-04-02       Impact factor: 4.339

3.  Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample.

Authors:  Lydia Chwastiak; Dawn M Ehde; Laura E Gibbons; Mark Sullivan; James D Bowen; George H Kraft
Journal:  Am J Psychiatry       Date:  2002-11       Impact factor: 18.112

4.  Rates of depression and anxiety in urban and rural Canada.

Authors:  Sarah Romans; Marsha Cohen; Tonia Forte
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2010-04-09       Impact factor: 4.328

5.  Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.

Authors:  R H S R Roxburgh; S R Seaman; T Masterman; A E Hensiek; S J Sawcer; S Vukusic; I Achiti; C Confavreux; M Coustans; E le Page; G Edan; G V McDonnell; S Hawkins; M Trojano; M Liguori; E Cocco; M G Marrosu; F Tesser; M A Leone; A Weber; F Zipp; B Miterski; J T Epplen; A Oturai; P Soelberg Sørensen; E G Celius; N Téllez Lara; X Montalban; P Villoslada; A M Silva; M Marta; I Leite; B Dubois; J Rubio; H Butzkueven; T Kilpatrick; M P Mycko; K W Selmaj; M E Rio; M Sá; G Salemi; G Savettieri; J Hillert; D A S Compston
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

6.  The utility of administrative data for surveillance of comorbidity in multiple sclerosis: a validation study.

Authors:  Ruth Ann Marrie; Bo Nancy Yu; Stella Leung; Lawrence Elliott; Patricia Caetano; Sharon Warren; Christina Wolfson; Scott B Patten; Lawrence W Svenson; Helen Tremlett; John Fisk; James F Blanchard
Journal:  Neuroepidemiology       Date:  2012-10-24       Impact factor: 3.282

Review 7.  HIV disease progression: depression, stress, and possible mechanisms.

Authors:  Jane Leserman
Journal:  Biol Psychiatry       Date:  2003-08-01       Impact factor: 13.382

Review 8.  Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: comparison with schizophrenia.

Authors:  A Carlo Altamura; Massimiliano Buoli; Sara Pozzoli
Journal:  Psychiatry Clin Neurosci       Date:  2013-09-19       Impact factor: 5.188

9.  Structural brain abnormalities in multiple sclerosis patients with major depression.

Authors:  A Feinstein; P Roy; N Lobaugh; K Feinstein; P O'Connor; S Black
Journal:  Neurology       Date:  2004-02-24       Impact factor: 9.910

10.  The relation between inflammation and neurodegeneration in multiple sclerosis brains.

Authors:  Josa M Frischer; Stephan Bramow; Assunta Dal-Bianco; Claudia F Lucchinetti; Helmut Rauschka; Manfred Schmidbauer; Henning Laursen; Per Soelberg Sorensen; Hans Lassmann
Journal:  Brain       Date:  2009-03-31       Impact factor: 13.501

View more
  28 in total

1.  Depression Comorbid With Stroke, Traumatic Brain Injury, Parkinson's Disease, and Multiple Sclerosis: Diagnosis and Treatment.

Authors:  Susan K Conroy; Katherine B Brownlowe; Thomas W McAllister
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-04-23

2.  NARCOMS and Other Registries in Multiple Sclerosis: Issues and Insights.

Authors:  Ruth Ann Marrie; Gary R Cutter; Robert J Fox; Timothy Vollmer; Tuula Tyry; Amber Salter
Journal:  Int J MS Care       Date:  2021-12-29

Review 3.  The manifestation of affective symptoms in multiple sclerosis and discussion of the currently available diagnostic assessment tools.

Authors:  Melanie Filser; Axel Buchner; Gereon Rudolf Fink; Stefan M Gold; Iris-Katharina Penner
Journal:  J Neurol       Date:  2022-09-21       Impact factor: 6.682

4.  The prevalence of comorbidities in patients with multiple sclerosis: population-based registry data.

Authors:  Gorica D Maric; Tatjana D Pekmezovic; Sarlota T Mesaros; Olivera S Tamas; Jovana B Ivanovic; Vanja N Martinovic; Marko M Andabaka; Aleksa Lj Jovanovic; Nikola D Veselinovic; Darija B Kisic-Tepavcevic; Jelena S Drulovic
Journal:  Neurol Sci       Date:  2020-09-22       Impact factor: 3.307

5.  Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis.

Authors:  Stefano Magon; Charidimos Tsagkas; Laura Gaetano; Raihaan Patel; Yvonne Naegelin; Michael Amann; Katrin Parmar; Athina Papadopoulou; Jens Wuerfel; Christoph Stippich; Ludwig Kappos; M Mallar Chakravarty; Till Sprenger
Journal:  J Neurol       Date:  2020-02-10       Impact factor: 4.849

6.  Socioeconomic status and race are correlated with affective symptoms in multiple sclerosis.

Authors:  Yujie Wang; Fan Tian; Kathryn C Fitzgerald; Jagriti Jackie Bhattarai; Robert T Naismith; Megan Hyland; Peter A Calabresi; Ellen M Mowry
Journal:  Mult Scler Relat Disord       Date:  2020-02-14       Impact factor: 4.339

7.  Effect of Exercise Interventions on Anxiety in People with Multiple Sclerosis: A Systematic Review and Meta-analysis.

Authors:  Claudia Gascoyne; Amalia Karahalios; Thibaut Demaneuf; Claudia Marck
Journal:  Int J MS Care       Date:  2019-08-07

8.  Mendelian randomization provides no evidence for a causal role in the bidirectional relationship between depression and multiple sclerosis.

Authors:  Adil Harroud; Ruth Ann Marrie; Kathryn C Fitzgerald; Amber Salter; Yi Lu; Mitulkumar Patel; Kaarina Kowalec
Journal:  Mult Scler       Date:  2021-02-16       Impact factor: 6.312

Review 9.  Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis.

Authors:  Laura E Baldassari; Robert J Fox
Journal:  Drugs       Date:  2018-10       Impact factor: 11.431

10.  Functional Electrical Stimulation Cycling Exercise in People with Multiple Sclerosis: Secondary Effects on Cognition, Symptoms, and Quality of Life.

Authors:  Lara A Pilutti; Thomas Edwards; Robert W Motl; Emerson Sebastião
Journal:  Int J MS Care       Date:  2019 Nov-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.